| Similar Articles |
|---|
 |
Nurse Practitioner
April 2010
McCravy et al. |
Speak the language of autism Autism affects 1 in 110 children and 1 in 70 boys in the United States.   |
HHMI Bulletin
May 2011
Madeline Drexler |
Mark Bear: Charting New Waters Bear has applied his discoveries in brain plasticity to understanding fragile X syndrome, an inherited form of mental impairment. |
Wired
February 25, 2008
David Wolman |
The Truth About Autism: Scientists Reconsider What They Think They Know The language of autism. |
Wired
December 2001
Steve Silberman |
The Geek Syndrome Autism -- and its milder cousin Asperger's syndrome -- is surging among the children of Silicon Valley. Are math-and-tech genes to blame? |
Salon.com
March 9, 2000
Lawrence H. Diller, M.D. |
Kids on drugs A behavioral pediatrician questions the wisdom of medicating our children. |
Wired
September 2001
Sara Solovitch |
The Citizen Scientists United by the Net and emboldened by their numbers, parents of desperately ill children are funneling millions into research, building vast genetic databases, and rewriting the rules of the medical industry.... |
Chemistry World
September 13, 2012
Ian Le Guillou |
Hope for autism treatments Two reports in Science over the past week point the way to potential treatments for some forms of autism. |
American Family Physician
November 1, 2002
Prater & Zylstra |
Autism: A Medical Primer Autistic disorder, a pervasive developmental disorder resulting in social, language, or sensorimotor deficits, occurs in approximately seven of 10,000 persons. Early detection and intervention significantly improve outcome. |
Salon.com
April 13, 1999
Arthur Allen |
Heal thyself.com Heal thyself.com: As wired patients go online for medical help, the question is: Can a little knowledge be a dangerous thing? |
BusinessWeek
September 5, 2005
Capell & Arndt |
Drugs Get Smart Future medicines will more effectively target what ails you by tailoring treatment to your specific genetic profile. Personalized medicine will also help prevent another Vioxx. |
Wired
December 2001
Oliver Morton |
Think Different? Autism researcher Simon Baron-Cohen on "mindblind" engineers, hidden pictures, and a future designed for people with Asperger's... |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age... |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
Reason
October 2005
Maia Szalavitz |
In Defense of Happy Pills While psychotherapy validated by research has its place, there is no convincing reason why it should be considered inherently superior to drugs. Pleasure can be just as important for emotional recovery and growth as pain, if not more so. |
Investment Advisor
December 2005
Greg B. Scott |
Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns. |
HHMI Bulletin
February 2012
Nicole Kresge |
Protein Precision in the Brain with CSF Two causes of autism arise from opposite cellular mechanisms. Too much or too little protein production at the synapse between neurons can cause autism and intellectual disability. |
American Family Physician
November 1, 2002 |
What You Should Know About Autism What is autism?... How can I tell if my child is autistic?... How is autism treated?... Where can I get more information?... |
| AskMen.com |
Can You Recover From Autism? Skeptics question the phenomenon, but a small, provocative study suggests that at least 10 percent of children with autism overcome the disorder by age 9. |
Salon.com
August 2, 2000
Lesli Mitchell |
Secrets and lies Is the astonishing rise in autism a medical mystery or a pharmaceutical shame? |
AskMen.com
Richard Stevens |
Participating In Clinical Trials Check out what participating in clinical trials involves and how you can join a study. You may even make some cash in the process. |
The Motley Fool
August 31, 2009
Brian Orelli |
Don't Let Dummy Pills Make You a Dummy Investor Instead of being scared that the sugar pill will perform better than expected, pharma investors should factor it in and require more information before investing in companies with drugs that may be affected by it.. |
Chemistry World
April 2008
Derek Lowe |
Column: In the Pipeline The recent row over antidepressants reminds us how little we know about the brain. |
Managed Care
June 2004 |
Use of Attention-Deficit Medications Surges 369 Percent in Children Under 5 ADHD medication spending for pediatric patients outpaces antibiotics, allergy, and asthma treatments. |
The Motley Fool
March 1, 2007
Brian Lawler |
Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works. |
BusinessWeek
October 18, 2004
Catherine Arnst |
The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma |
BusinessWeek
February 9, 2004
John Carey |
Drug Ads Need Stronger Medicine New FDA guidelines may not go far enough in making sure pharmaceutical ads are used appropriately. |
Popular Mechanics
February 11, 2010
Adam Hadhazy |
The Truth About 9 Anti-Vaccine Studies Led by celebrities such as Jenny McCarthy, the anti-vaccine movement continues to vehemently oppose mainstream science's overwhelming consensus that vaccines do not cause developmental disorders. |
Wired
March 23, 2009
Jonah Lehrer |
Scientists Map the Brain, Gene by Gene I'm in the dissection room of the Allen Institute for Brain Science in Seattle, and the scientist next to me is in a hurry. |
Bio-IT World
August 13, 2003
John Rhodes |
Beyond the Blockbuster Genomics and big hits are not mutually exclusive, writes Deloitte & Touche's life sciences expert. |
BusinessWeek
December 11, 2006
Michael Arndt |
Kills Pain, Cures Rabies, And Grows Hair The prescription drug market is one part Big Brother and one part Wild West. |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities. |
The Motley Fool
April 9, 2009
Brian Orelli |
The Side Effects of Competition In the pharmaceutical business, it's often the competitors that determine how bad the side effects can be. |
Wired
December 2003
Steve Silberman |
The Key to Genius Autistic savants are born with miswired neurons - and extraordinary gifts. The breakthrough science behind our new understanding of the brain |
The Motley Fool
May 16, 2007
Mike Havrilla |
Nastech Nose Potential The small biotech reports the achievement of positive results for carbetocin nasal spray for the treatment of autism symptoms along with the completion of a $41 million stock offering in January. |
BusinessWeek
June 28, 2004
Amy Barrett |
When Medicine And Money Don't Mix Do drugmakers have too much control over lab data? |
The Motley Fool
September 7, 2007
Brian Orelli |
Clinical Data Gets Personal Clinical Data's lead compound Vilazodone posts strong phase 3 results. The company is searching for common genetic markers among patients who responded positively to the drug. |
The Motley Fool
October 9, 2006
Brian Lawler |
The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field. |
IEEE Spectrum
October 2006
Philip E. Ross |
When Engineers' Genes Collide Could modern patterns of marriage be concentrating the genes that predispose people to autism? |
The Motley Fool
February 25, 2009
Brian Orelli |
Pfizer Doesn't Like Reruns The company drops two drugs that had made it as far as phase 3 trials. |
AskMen.com
Jacob Franek |
Asperger's Syndrome Asperger's syndrome is actually named after an Austrian physician, Hans Asperger, who first described the strange disorder in 1944. Like classical autism, A.S. belongs to a class of disorders known as autism spectrum disorders. |
Wired
March 2006
Jennifer Kahn |
A Nation of Guinea Pigs There's a new outsourcing boom in South Asia - and a billion people are jockeying for the jobs. How India became the global hot spot for drug trials. |
Pharmaceutical Executive
July 30, 2007
Louis A. Morris |
Safety Net The new Culture of Drug Safety means embracing the benefit of no doubt about a product's pluses and its minuses. Pharma must learn how patients and prescribers weigh risks and how to spread the word about the advantages. |
The Motley Fool
September 5, 2007
Billy Fisher |
Lilly's Pipeline Continues to Produce Another schizophrenia drug from the company shows promise in a clinical trial, prompting the company to plan additional trials. This is the latest good news in what has been a good year for Lilly. |
Salon.com
April 13, 2000
Arthur Allen |
Inoculated into oblivion When families hit the Capitol last week, they demanded answers about the source of their children's autism. |
Reason
April 2001
Ronald Bailey |
Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry? |
The Motley Fool
April 24, 2009
Brian Orelli |
Great Drugs Not Living Up to Their Potential How well a drug works is not the most important thing to consider when investing. Drugs that work don't always become blockbusters. |
Salon.com
August 2, 2000
Arthur Allen |
A recipe for disaster While nobody knows the origin of autism, many researchers worry that linking it to childhood vaccines could be a very dangerous theory. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
BusinessWeek
September 5, 2005 |
Putting the FDA Out Front Deputy Commissioner Dr. Janet Woodcock explains how the agency has led the drive for personalized medicine. |
The Motley Fool
April 12, 2004
Brian Gorman |
Forest Labs Faces Skeptics Its star drug Namenda, a new treatment for Alzheimer's disease, is taking heat from doctors. |
